^
Association details:
| Biomarker: | SOX9 overexpression |
|---|---|
| Cancer: | Esophageal Squamous Cell Carcinoma |
| Drug: | Fyarro (nanoparticle albumin-bound rapamycin) (mTORC1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SOX9/miR-203a axis drives PI3K/AKT signaling to promote esophageal cancer progression
Excerpt:
The inhibition effect of rapamycin was also stronger on tumor xenografts from Eca109-SOX9 cells than that from Eca109-vector cells (Fig. 6F), indicating that rapamycin exerted an enhanced anti-tumor effect on ESCC cells with high SOX9 level....The observation that the PI3K/AKT/mTOR signatures were enriched in clinical ESCC samples with high SOX9 expression further suggests a potential role for the PI3K/AKT/mTOR pathway in SOX9-induced esophageal cancer progression.
DOI:
https://doi.org/10.1016/j.canlet.2019.10.004
